Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited (ZURA) is a clinical-stage biotechnology company advancing novel therapies for immune and inflammatory disorders, with its lead candidate zb-168 targeting IL7rα pathways. This page serves as the definitive source for verified company news and developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection ensures access to essential updates while maintaining scientific accuracy and regulatory compliance.
Key content includes phase trial results, research collaborations, and mechanism-of-action studies related to zb-168's potential in treating alopecia areata and other immune-mediated conditions. All materials are vetted for relevance to therapeutic development timelines.
Bookmark this page for streamlined access to Zura Bio's latest scientific advancements and corporate announcements. Regularly updated to reflect material developments in immune modulation research.
Zura Bio (NASDAQ: ZURA) reported its full year 2024 financial results, highlighting significant operational and financial achievements. The company completed a $112.5 million private placement in April 2024, ending the year with $176.5 million in cash and cash equivalents, providing runway through 2027.
Key developments include initiating the Phase 2 TibuSURE trial for systemic sclerosis and plans to launch a Phase 2 study for hidradenitis suppurativa in Q2 2025. Financial results show R&D expenses decreased to $24.4 million from $44.0 million in 2023, while G&A expenses increased to $30.8 million from $18.6 million. The company reported a net loss of $45.4 million ($0.60 per share) compared to $69.2 million ($2.09 per share) in 2023.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. The company's senior leadership team will engage in a fireside chat on Tuesday, March 11, 2025, at 1:40 p.m. ET in Miami, FL, where they will also host investor meetings.
The presentation will be accessible through a live webcast on the News & Events page of Zura Bio's website's Investors & Media section. For those unable to attend, a replay will be available and archived on the website for a minimum of 30 days after the event.
Zura Bio (NASDAQ: ZURA) has launched TibuSURE, a global Phase 2 study evaluating tibulizumab for treating systemic sclerosis (SSc) in adults. The study marks the first clinical trial designed to investigate both anti-BAFF and IL-17 pathways in systemic sclerosis. Tibulizumab's dual-pathway approach aims to provide deeper efficacy compared to single-pathway inhibition, which has shown modest effects in rheumatic diseases like SSc.
The company believes this novel strategy of concurrently targeting two pivotal pathways involved in inflammation and fibrosis could address the multi-organ pathology of SSc, a heterogeneous and complex autoimmune disease with effective therapies currently available.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focusing on dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior leadership team will engage in a fireside chat on Tuesday, December 3, 2024, at 9:00 a.m. ET in New York, NY, and will conduct investor meetings. A live webcast and replay of the presentation will be accessible on the company's website's Investors section under 'News & Events,' remaining available for at least 30 days after the event.
Zura Bio (Nasdaq: ZURA) has submitted a protocol to the FDA for a Phase 2 study of tibulizumab, a dual-pathway antibody targeting IL-17A and BAFF, for treating systemic sclerosis in adults. The planned double-blind, randomized study will evaluate safety, tolerability, and efficacy in approximately 80 participants with early diffuse cutaneous systemic sclerosis. The trial aims to demonstrate improvements in skin and lung symptoms and includes an open-label extension. Expected to begin in Q4 2024, the company has already submitted an Orphan Drug Designation request to the FDA.
Zura Bio (NASDAQ: ZURA) reported Q3 2024 financial results with a net loss of $22.9 million ($0.26 per share), compared to $8.3 million ($0.18 per share) in Q3 2023. The company maintains a strong cash position of $188.2 million, expected to fund operations through 2027. Research and development expenses increased to $6.0 million, while general and administrative expenses rose to $13.3 million.
The company plans to initiate Phase 2 trials for tibulizumab in systemic sclerosis (Q4 2024) and hidradenitis suppurativa (Q2 2025). An Orphan Drug Designation application was submitted to the FDA for systemic sclerosis treatment.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in two major investor conferences this November. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 1:00 p.m. ET in Boston, and will host investor meetings at the Jefferies London Healthcare Conference on November 21, 2024, in London. Webcasts and replays will be available on Zura Bio's website's News & Events page for at least 30 days after the events.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced its participation in three upcoming investor conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 11:30 a.m. ET, the Stifel Immunology and Inflammation Virtual Summit on September 17 at 12:00 p.m. ET, and the Cantor Global Healthcare Conference on September 17 at 2:30 p.m. ET.
Zura Bio's senior leadership team will host investor meetings at these events, with the Stifel summit being virtual. Live webcasts and replays of the presentations will be available on the company's website for at least 30 days following each event.
Zura Bio (Nasdaq: ZURA) reported Q2 2024 financial results and business highlights. Key points include:
- Presented tibulizumab data at EULAR 2024, showing potential for dual inhibition of IL-17A and BAFF in autoimmune diseases
- Plans to initiate Phase 2 studies for tibulizumab in systemic sclerosis (Q4 2024) and hidradenitis suppurativa (Q2 2025)
- Appointed Robert Lisicki as CEO and formed Scientific Advisory Board
- Cash position of $188.4 million as of June 30, 2024, expected to support operations through 2027
- Q2 2024 net loss of $12.7 million ($0.17 per share)
- R&D expenses decreased to $5.5 million, while G&A expenses increased to $6.2 million
Zura Bio (Nasdaq: ZURA) has completed its exchange offer and consent solicitation for outstanding public and private placement warrants. The company issued 3,235,184 ordinary shares in exchange for tendered IPO warrants. Zura Bio will exercise its right to exchange all remaining untendered IPO warrants at a ratio of 0.27 Class A ordinary shares per warrant on August 27, 2024. As a result, no IPO warrants will remain outstanding, leading to their suspension from trading on Nasdaq as of August 26, 2024, and subsequent delisting. The company's Class A ordinary shares will continue to trade on Nasdaq under the symbol 'ZURA'.
